

excluding only the serologic laboratory parameters from cSLE-DAI-2K. Including both clinical laboratory parameters and manifestations provides a more complete understanding of patients' status.

**Methods** Patients with moderate to severe SLE despite standard therapy could consent after the 52-week TULIP-1/-2 trials to participate in the randomized, double-blind, 3-year LTE (NCT02794285). We analyzed patients randomized to intravenous anifrolumab 300 mg or placebo for the 4-year TULIP-LTE. In this new analysis, DORIS attainment was defined as total cSLEDAI-2K score (sum of all SLEDAI-2K items except increased DNA binding and low complement) =0, physician global assessment <0.5, prednisone/equivalent dosage ≤5 mg/day, stable maintenance immunosuppressant doses, no restricted medication use (TULIP-1/-2 only), and no premature investigational product discontinuation. DORIS attainment was calculated using a stratified Cochran-Mantel-Haenszel approach.

**Results** We analyzed 369 patients (anifrolumab, n=257; placebo, n=112) who continued treatment in the LTE. Using the new analysis described above, 19.7% of anifrolumab-treated patients attained DORIS at the first LTE visit (Week 64) compared with 9.9% of the placebo group (treatment difference, Δ [95% CI]=9.8% [0.6–19.1], nominal *P*=0.037); DORIS attainment rates increased from baseline throughout the trial (figure 1). Trends favoring anifrolumab versus placebo were observed up to Week 208 (30.3% vs 18.3%; Δ=12.0% [–0.6–24.6], nominal *P*=0.062).

**Conclusion** Remission is an important SLE treatment goal that protects from flares and organ damage. Anifrolumab treatment was associated with higher DORIS remission rates compared with placebo during the 4-year trial.

**Acknowledgments** Sponsor: AstraZeneca. Writing assistance: Rosie Butler, PhD, of JK Associates Inc. (Avalere Health).

## REFERENCE

- van Vollenhoven, Morand, Furie, *et al.* Remission in patients with SLE treated with anifrolumab compared with placebo over a 4-year period [abstract]. *Arthritis Rheumatol.* 2023;75[sup 9].

## LBO2 LONG-TERM RENAL AND CARDIOVASCULAR RISKS OF TACROLIMUS IN LUPUS NEPHRITIS PATIENTS

<sup>1</sup>Mieke van Schaik, <sup>1</sup>Obbo W Bredewold, <sup>1</sup>Merel Priester, <sup>2</sup>Wieneke M Michels, <sup>1</sup>Ton J Rabelink, <sup>2</sup>Joris I Rotmans, <sup>1</sup>YK Onno Teng. <sup>1</sup>Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Dept. of Nephrology, Leiden University Medical Center, Leiden, The Netherlands; <sup>2</sup>Dept. of Nephrology, Leiden University Medical Center, Leiden, The Netherlands

10.1136/lupus-2024-el.221

**Objective** Systemic lupus erythematosus is associated with an increased risk of cardiovascular disease. Tacrolimus is a calcineurin inhibitor that finds its origin in solid organ transplantation, but is also effectively used in lupus nephritis. In a transplant setting, tacrolimus is associated with an increased cardiovascular risk, including nephrotoxicity, hypertension, dyslipidemia and hyperglycemia. In lupus nephritis the use of tacrolimus is off-label, and since head-to-head comparisons and long-term evaluations are lacking, its safety profile is less well-defined. Our objective was to investigate the long-term

effects of tacrolimus on cardiovascular and renal outcomes in lupus nephritis patients.

**Methods** In a retrospective, single-center cohort study, all adult lupus nephritis patients treated in the Leiden University Medical Center between 2004 and 2023 were investigated and dichotomized based on the prescription of systemic tacrolimus. We evaluated the Framingham risk score and the occurrence of cardiovascular events, diabetes, dyslipidemia, and change in kidney function.

**Results** Of 223 patients that were enrolled in the study, 45 (20.2%) were ever prescribed tacrolimus. The remaining 178 patients had never been prescribed calcineurin inhibitors and were assigned to the control group. There was an equally low incidence of cardiovascular events in both groups. The 10-year risk of coronary heart disease was significantly lower in the tacrolimus group, although this could largely be contributed to the age difference between the groups. Tacrolimus use was an independent predictor of eGFR decline, but did not result in larger incidence of end-stage kidney disease during the follow-up period. There was no difference in the occurrence of diabetes or dyslipidemia between the groups, although there was a significant increase in HbA1c in the tacrolimus group.

**Conclusions** Tacrolimus may have nephrotoxic and modest diabetogenic effects in lupus nephritis patients. Caution when prescribing tacrolimus and vigilance towards these possible side effects when continuing tacrolimus treatment as maintenance treatment is advised. However, further prospective studies in larger cohorts are necessary to confirm these findings and further assess the side-effects of tacrolimus in lupus nephritis patients.

**Acknowledgements** Not applicable

## LBP1

## INTERIM RESULTS OF AN OPEN-LABEL, MULTICENTRE, PHASE 1/2 STUDY TO ASSESS YTB323 (RIPCABTAGENE AUTOLEUCEL), A CAR T-CELL THERAPY, FOR SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS

<sup>1,2</sup>Josefina Cortés Hernández, <sup>2,3</sup>Pere Barba, <sup>4,5,6</sup>José María Álvaro-Gracia Álvaro, <sup>7,8</sup>Mi Kwon, <sup>9</sup>Julia Weinmann-Menke, <sup>10</sup>Eva Wagner-Drouet, <sup>11</sup>Ozana Fischer, <sup>11</sup>Beata Kovacs, <sup>11</sup>Frédérique Chaperon, <sup>11</sup>David Pearson, <sup>11</sup>Tiina Kirsilä, <sup>12</sup>Chih-Yung Sean Lee, <sup>13</sup>Clive Drakeford, <sup>11</sup>Peter Gergely, <sup>11</sup>Giulio Cavalli, <sup>11</sup>Tamas Shisha. <sup>1</sup>VHIR- Vall d'Hebron Institute of Research, Barcelona, Spain; <sup>2</sup>Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; <sup>3</sup>Vall d'Hebron Institute of Oncology, Barcelona, Spain; <sup>4</sup>Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain; <sup>5</sup>Dept. of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; <sup>6</sup>Faculty of Medicine, Complutense University of Madrid, Madrid, Spain; <sup>7</sup>Dept. of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; <sup>8</sup>Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain; <sup>9</sup>University Medical Center of the Johannes Gutenberg University, Mainz, Germany; <sup>10</sup>rd Medical Dept., University Medical Center of the Johannes Gutenberg-University Mainz, Germany; <sup>11</sup>Novartis Biomedical Research, Basel, Switzerland; <sup>12</sup>Novartis Biomedical Research, Cambridge, MA, USA; <sup>13</sup>Novartis Ireland Limited, Dublin, Ireland

10.1136/lupus-2024-el.222

**Objective** Patients with severe refractory systemic lupus erythematosus (srSLE) exhibit failure to respond to treatments, progressive organ damage, and high mortality. Traditionally manufactured CD19-directed CAR T-cell therapies have potential to promote full clinical remission in srSLE. YTB323 (rapcabtogene autoleucel) is a novel, rapidly manufactured,